Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression

Objective Monoamine oxidase-A (MAO-A) is a key mitochondrial enzyme that metabolizes biogenic amine neurotransmitters such as dopamine and serotonin. Individuals with atypical depression (AD) are particularly responsive to treatment with MAO inhibitors (MAOIs). Biomarker tests are essential for prompt diagnosis of AD, and to identify those with an altered brain neurotransmitter metabolism who may selectively respond to MAOI therapy. Methods In a sample of 118 Scandinavian patients with treatment-resistant depression who are naive to MAOI therapy, we investigated the associations between a common MAOA functional promoter polymorphism (MAOA-uVNTR), cerebrospinal fluid (CSF) neurotransmitter metabolites, and AD susceptibility. The metabolites for dopamine (homovanillic acid, HVA), serotonin (5-hydroxyindoleacetic acid) and noradrenaline (3-methoxy-4-hydroxyphenylglycol) were measured in the CSF. Results AD was associated with the female sex and a higher HVA in CSF (P=0.008). The carriers of the MAOA-uVNTR short allele were significantly overrepresented among women with AD (P=0.005; odds ratio=4.76; 95% confidence interval=1.5–13.1; statistical power=80.0%). Moreover, the MAOA-uVNTR genotype significantly influenced the HVA concentration (P=0.01) and showed a strong trend in relation to 5-hydroxyindoleacetic acid concentration (P=0.057) in women. The mediational statistical analyses showed the CSF-HVA concentration as a key driver of the relationship between MAOA-uVNTR genotype and AD. Conclusion The association of the MAOA-uVNTR with both susceptibility to AD and dopamine metabolite (HVA) concentration lends further biological plausibility for high MAO-A enzyme activity as a mechanistic factor for genetic predisposition to AD through altered dopamine turnover. Our observations provide new evidence on the in-vivo functional significance of the MAOA-uVNTR short allele as a high activity variant.

[1]  T. Brewerton,et al.  Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes. , 1992, Archives of general psychiatry.

[2]  J. Haines,et al.  Human monoamine oxidase gene (MAOA): chromosome position (Xp21-p11) and DNA polymorphism. , 1988, Genomics.

[3]  P. Sullivan,et al.  The subtypes of major depression in a twin registry. , 2002, Journal of affective disorders.

[4]  F. Benazzi.  Prevalence and clinical features of atypical depression in depressed outpatients: a 467-case study , 1999, Psychiatry Research.

[5]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[6]  M. First,et al.  The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. , 1992, Archives of general psychiatry.

[7]  Jeremy Veenstra-Vander Weele,et al.  Serotonin Transporter and Seasonal Variation in Blood Serotonin in Families with Obsessive-Compulsive Disorder , 1998, Neuropsychopharmacology.

[8]  P J McGrath,et al.  Atypical depression. A valid clinical entity? , 1993, The Psychiatric clinics of North America.

[9]  J. Davidson,et al.  Depression with atypical features in the National Comorbidity Survey: classification, description, and consequences. , 2003, Archives of general psychiatry.

[10]  K. Gadde,et al.  Serotonin-Related Gene Polymorphisms and Central Nervous System Serotonin Function* , 2003, Neuropsychopharmacology.

[11]  F. Benazzi.  Can only reversed vegetative symptoms define atypical depression? , 2002, European Archives of Psychiatry and Clinical Neuroscience.

[12]  M. Åsberg,et al.  Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. , 2004, Journal of psychiatric research.

[13]  G. Zalsman,et al.  Relationship of MAO‐A promoter (u‐VNTR) and COMT (V158M) gene polymorphisms to CSF monoamine metabolites levels in a psychiatric sample of caucasians: A preliminary report , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[14]  L. Bertilsson,et al.  Monoamine Metabolites Level in CSF is Related to the 5-HTT Gene Polymorphism in Treatment-Resistant Depression , 2007, Neuropsychopharmacology.

[15]  M. Wong,et al.  Corticotropin Releasing Hormone in the Pathophysiology of Melancholic and Atypical Depression and in the Mechanism of Action of Antidepressant Drugs , 1995, Annals of the New York Academy of Sciences.

[16]  M. Thase,et al.  Treating DSM-IV depression with atypical features. , 2007, The Journal of clinical psychiatry.

[17]  B. Grant,et al.  Are overweight, obesity, and extreme obesity associated with psychopathology? Results from the national epidemiologic survey on alcohol and related conditions. , 2007, The Journal of clinical psychiatry.

[18]  Yoshiro Okubo,et al.  No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET , 2003, Synapse.

[19]  G. Asnis,et al.  Biological and clinical validation of atypical depression , 1996, Psychiatry Research.

[20]  J. Endicott,et al.  [Schedule for Affective Disorders and Schizophrenia (SADS)]. , 1987, Acta psychiatrica Belgica.

[21]  D. Goldman,et al.  A functional polymorphism in the MAOA gene promoter (MAOA-LPR) predicts central dopamine function and body mass index , 2006, Molecular Psychiatry.

[22]  H. Möller,et al.  Treatment of depression with atypical features: A meta-analytic approach , 2006, Psychiatry Research.

[23]  M Linnoila,et al.  Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. , 1986, Journal of psychiatric research.

[24]  K. Kendler,et al.  Genetic risk factors for major depression in men and women: similar or different heritabilities and same or partly distinct genes? , 2001, Psychological Medicine.

[25]  B. McEwen,et al.  Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain , 1975, Brain Research.

[26]  D. A. Kenny,et al.  The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. , 1986, Journal of personality and social psychology.

[27]  J. Mann,et al.  An Association between a Functional Polymorphism in the Monoamine Oxidase A Gene Promoter, Impulsive Traits and Early Abuse Experiences , 2004, Neuropsychopharmacology.

[28]  L. Bierut,et al.  Major depressive disorder in a community-based twin sample: are there different genetic and environmental contributions for men and women? , 1999, Archives of general psychiatry.

[29]  J. Endicott,et al.  Diagnostic interview schedule: reliability and validity. , 1981, Archives of general psychiatry.

[30]  M. Nöthen,et al.  Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. , 1999, Human molecular genetics.

[31]  D Winkler,et al.  A polymorphism (5-HTTLPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder , 2003, Molecular Psychiatry.

[32]  J. Shih,et al.  Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.

[33]  R. Kessler,et al.  The identification and validation of distinct depressive syndromes in a population-based sample of female twins. , 1996, Archives of general psychiatry.

[34]  M. Thase.  Recognition and diagnosis of atypical depression. , 2007, The Journal of clinical psychiatry.

[35]  A. Gamma,et al.  Atypical depressive syndromes in varying definitions , 2006, European Archives of Psychiatry and Clinical Neuroscience.

[36]  K. Blennow,et al.  Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18–88 years of age , 1993, European Neuropsychopharmacology.

[37]  K. Merikangas,et al.  Toward validation of atypical depression in the community: results of the Zurich cohort study. , 2002, Journal of affective disorders.

[38]  M. Fava,et al.  Course and treatment of atypical depression. , 1998, The Journal of clinical psychiatry.

[39]  W. Sanderson,et al.  Atypical depression: clinical aspects and noradrenergic function. , 1995, The American journal of psychiatry.

[40]  E. Paykel,et al.  Genetic associations with clinical characteristics in bipolar affective disorder and recurrent unipolar depressive disorder. , 2000, American journal of medical genetics.

[41]  S. Tsai,et al.  Association Study of a Monoamine Oxidase A Gene Promoter Polymorphism with Major Depressive Disorder and Antidepressant Response , 2005, Neuropsychopharmacology.

[42]  D. Klein,et al.  The identification and validation of distinct depressive syndromes in a population-based sample of female twins. , 1997, Archives of general psychiatry.

[43]  Volker Arolt,et al.  Serotonin transporter polymorphism (5‐HTTLPR) association with melancholic depression: a female specific effect? , 2008, Depression and anxiety.

[44]  D. Hamer,et al.  A functional polymorphism in the monoamine oxidase A gene promoter , 1998, Human Genetics.

[45]  T G Schulze,et al.  Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. , 2000, American journal of medical genetics.

[46]  E. Lindström,et al.  SCID II interviews and the SCID Screen questionnaire as diagnostic tools for personality disorders in DSM‐III‐R , 1994, Acta psychiatrica Scandinavica.

[47]  M. Stanley,et al.  Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. , 1985, Life sciences.

[48]  J. Shih,et al.  Role of MAO A and B in neurotransmitter metabolism and behavior. , 1999, Polish journal of pharmacology.

[49]  F. Quitkin.  Depression With Atypical Features: Diagnostic Validity, Prevalence, and Treatment. , 2002, Primary care companion to the Journal of clinical psychiatry.

[50]  David Goldman,et al.  Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. , 2006, The American journal of psychiatry.

[51]  M J Owen,et al.  A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. , 2000, Journal of psychiatric research.

[52]  Sylvain Houle,et al.  Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. , 2006, Archives of general psychiatry.

[53]  L. Iversen.  Neurotransmitter transporters: fruitful targets for CNS drug discovery , 2000, Molecular Psychiatry.

[54]  J. Flory,et al.  A regulatory polymorphism of the monoamine oxidase-A gene may be associated with variability in aggression, impulsivity, and central nervous system serotonergic responsivity , 2000, Psychiatry Research.